<DOC>
	<DOCNO>NCT00430508</DOCNO>
	<brief_summary>The study evaluate blood pressure lower effect two different dosage combination olmesartan hydrochlorothiazide patient moderate severe high blood pressure .</brief_summary>
	<brief_title>Use Combination Olmesartan Hydrochlorothiazide Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Male female Europeans age 18 year old moderate severe hypertension ( HTN ) Female patient childbearing potential pregnant , lactate plan become pregnant trial period . Patients serious disorder may limit ability evaluate efficacy safety study medication , include cerebrovascular , cardiovascular , renal , respiratory , hepatic , gastrointestinal , endocrine metabolic , haematological oncological , neurological psychiatric disease . Patients history follow within last six month : myocardial infarction , unstable angina pectoris , percutaneous coronary intervention , severe heart failure , hypertensive encephalopathy , cerebrovascular accident ( stroke ) transient ischaemic attack . Patients clinically significant abnormal laboratory value screen . Patients secondary HTN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Moderate-to-Severe Hypertension</keyword>
	<keyword>Essential Hypertension</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Fixed-Combination Dose</keyword>
</DOC>